Results of the Combined General Meeting of November 13, 2025

All resolutions presented by the Company have been adopted

Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and Extraordinary General Meeting.

Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 31% of the shareholders present or represented. The resolutions notably included the approval of the financial statements of the fiscal year 2024.

The results of the votes are available on the Biophytis website in the “General Meetings” section.

Fullscreen Mode

Other Press Releases

All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and…

Read more

Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…

Read more

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…

Read more

Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events…

Read more

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial…

Read more

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial…

Read more